work-life balance, translational science, industry, data sharing
Blue Rush: One Company Leads the Race to Own Marine Genetic Sequences
Blue Rush: One Company Leads the Race to Own Marine Genetic Sequences
Ruth Williams | Jun 6, 2018
Almost half of all patents relating to the genes of marine organisms belong to one large international corporation, BASF, a new study reveals.  
Canadian Scientists Least Likely to Share Data: Survey
Canadian Scientists Least Likely to Share Data: Survey
Kerry Grens | Apr 2, 2018
Americans and Australians aren’t far behind, according to a questionnaire of researchers.
How to Successfully Collaborate with Industry
How to Successfully Collaborate with Industry
Ashley P. Taylor | Mar 1, 2018
In efforts to translate basic-science results into pharmaceuticals and other technologies, success cannot be taken for granted.
Can Young Stem Cells Make Older People Stronger?
Can Young Stem Cells Make Older People Stronger?
Shawna Williams | Dec 11, 2017
Small trials using younger donors and elderly recipients hint that mesenchymal stem cell transfers might reduce frailty. 
Editors Claim Censorship at a Public Health Journal
Editors Claim Censorship at a Public Health Journal
Jef Akst | Nov 21, 2017
The editorial board at the International Journal of Occupational and Environmental Health accuses its publisher of promoting corporate interests.
2017 Life Science Salary Survey
2017 Life Science Salary Survey
Aggie Mika | Nov 1, 2017
Industry professionals make more than academic researchers, but for professors, it may not be about the money.
Opinion: Share Your Data
Opinion: Share Your Data
Cameron Craddock, Arno Klein, Michael P. Milham | Oct 24, 2017
Our analysis of a collection of open-access datasets quantifies their benefit to the scientific community.
Opinion: Tales from the Nonacademic Career Path
Opinion: Tales from the Nonacademic Career Path
Anna Kriebs | Sep 3, 2017
Graduate students from The Scripps Research Institute share how they prepared to enter policy, law, biotech, and beyond.
Gilead to Pay Nearly $12B for CAR T-Cell Company
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
Making Public Data Public
Making Public Data Public
Ruth Williams | Jun 8, 2017
Computational scientists develop a system for spotting data overdue for public release, and end up getting hundreds of open-access datasets corrected.